Switzerland· 56395006

Glivec

A imatinib product containing imatinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EA01

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedGlivecATCL01EA01REGISTER NO.56395006PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Imatinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EA01 (imatinib), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Imatinib · ATC L01EA01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of imatinib costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $2.80 in United States to $41.72 in Switzerland — a ×15 gap.

  • Switzerland: $41.72 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Imatinib · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$41.72
  • IT Italy$11.38
  • US United States$2.80 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
imatinibum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01EA01
ATC class
Imatinib
Defined daily dose
0.4 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680563950061
    30 Stk
    CHF 1730.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

766 interactions on record for imatinib.

Graded by severity as the source publishes them — 114 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Imatinib · interactions on record

766 records

  • 114 severe
  • 518 moderate
  • 23 minor
  • 111 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Imatinib in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imatinib products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Imagerolan, Imatinib 1a Pharma
  • Belgium · Imatinib Eg, Imatinib Grindeks
  • Bulgaria · Иматиниб Тева Фарма, Меаксин
  • Cyprus · Imarem, Imatinib Koanaa 100 Mg
  • Czechia · Imanivec, Imatinib Grindeks
  • Germany · Imanivec, Imatinib 1 A Pharma
  • Denmark · Bimatix, Imatinib "sandoz"
  • Estonia · Glipox, Imatinib Grindeks
  • Spain · Imatinib Cipla, Imatinib Farmalider
  • Finland · Bimatix, Imatinib Hexal
  • France · Imatinib Arrow Lab, Imatinib Bgr
  • United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
  • Greece · Imatek, Imatinib Aenorasis
  • Croatia · Imakrebin, Meaxin
  • Hungary · Imaniver, Imatinib 1 A Pharma
  • Ireland · Imatinib Krka D.D., Imatinib Rowex
  • Iceland · Bimatix, Glivec
  • Italy · Imanivec, Imatinib Dr. Reddy’s
  • Liechtenstein · Glivec, Imatinib Accord
  • Lithuania · Glipox, Imatinib Grindeks
  • Luxembourg · Imatinib, Imatinib Eg
  • Latvia · Imatinib Grindeks, Imatinib Inteli
  • Malta · Imatinib Tad, Nibix
  • Netherlands · Bimatix, Imakrebin
  • Norway · Bimatix, Glivec
  • Poland · Imatenil, Meaxin
  • Portugal · Imatinib Aurobindo, Imatinib Aurovitas
  • Romania · Imakrebin, Imatinib Grindeks
  • Sweden · Bimatix, Imatinib Amarox
  • Slovenia · Meaxin
  • Slovakia · Imatinib Glenmark, Imatinib Grindeks

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a976def3-262d-4631-84f9-1dcd3732e3b0
GET /v1/drugs/a976def3-262d-4631-84f9-1dcd3732e3b0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "imatinibum 400 mg",
  "valid_from": "2009-05-01",
  "limitations": "[{\"description\":\"Behandlung von erwachsenen und pädiatrischen Patienten mit Ph+ chronisch-myeloischer Leukämie (Ph+CML) in der chronischen Phase, in der akzelerierten Phase sowie in der Blastenkrise.<br>\\nBehandlung von Erwachsenen und pädiatrischen Patienten mit Ph+ akuter lymphatischer Leukämie (Ph+ALL) in Kombination mit Standardchemotherapie.<br>\\nBehandlung von erwachsenen Patienten mit Hypereosinophilensyndrom (HES), atypischen myelodysplastischen/myeloproliferativen Erkrankungen (MDS/MPD) oder aggressiver systemischer Mastozytose (SM) einhergehend mit Eosinophilie und einer plated-derived growth factor (PDGF)-Rezeptor-alpha oder -beta Mutation oder einem FIP1L1-PDGFR-alpha Fusionsprotein.<br>\\nBehandlung von Erwachsenen mit unresezierbarem, rezidivierendem oder metastasierendem Dermatofibrosarkom protuberans (DFSP).\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2016-03-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 400 mg teilbar",
  "therapeutic_area": null,
  "sl_inclusion_date": "2009-05-01",
  "self_retention_pct": 40
}

See everything about imatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.